X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/04/30/2871996/29517/en/MannKind-to-Proceed-With-Phase-1-Nintedanib-Dpi-Mnkd-201-Study-for-Pulmonary-Fibrotic-Diseases.html
https://www.prnewswire.com/news-releases/us-fda-accepts-supplemental-new-drug-application-for-ofev-nintedanib-for-children-and-adolescents-aged-6-17-years-old-with-fibrosing-interstitial-lung-disease-301885030.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216915
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216915
https://www.pharmatimes.com/news/nice_approves_ofev_for_pf-ild_1381094
http://www.pharmafile.com/news/579686/smc-approves-nintedanib-patients-chronic-lung-disease
https://www.prnewswire.com/news-releases/study-analysis-available-during-ats-2021-supports-long-term-treatment-with-ofev-in-patients-with-systemic-sclerosis-associated-interstitial-lung-disease-301291485.html
https://www.newswire.ca/news-releases/ofev-r-nintedanib-receives-positive-recommendation-from-cadth-and-inesss-for-the-treatment-of-progressive-fibrosing-interstitial-lung-diseases-pf-ild--861661389.html
https://www.clinicaltrialsarena.com/news/boehringer-covid-19-trial/
https://www.cohbar.com/news-media/press-releases/detail/128/cohbar-antifibrotic-peptide-in-combination-with-nintedanib
https://www.cipla.com/cipla-launches-nintedanib-capsules-to-treat-idiopathic-pulmonary-fibrosis-a-rare-lung-diseases
https://www.clinicaltrialsarena.com/news/boehringer-nintedanib-paediatric/
https://www.prnewswire.com/news-releases/phase-iii-inpedild-trial-enrolls-first-patient-to-evaluate-nintedanib-in-pediatric-population-with-fibrosing-interstitial-lung-disease-301110440.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212732
https://www.prnewswire.com/news-releases/new-analyses-of-ofev-data-in-patients-with-chronic-fibrosing-ilds-available-during-american-thoracic-society-congress-301106964.html
https://www.businesswire.com/news/home/20200715005540/en/European-Commission-approves-nintedanib-indication-pulmonary-fibrosis1
https://www.newswire.ca/news-releases/ofev-r-nintedanib-now-available-in-canada-for-adults-living-with-progressive-fibrosing-interstitial-lung-diseases-pf-ild-1--832814578.html
https://www.news-medical.net/news/20200511/AI-VIVO-seeks-pharma-biotech-collaboration-partners-to-advance-drug-candidates-for-COVID-19.aspx
https://www.raps.org/news-and-articles/news-articles/2020/2/chmp-recommends-one-new-drug-begins-review-of-ind
https://www.pharmaceutical-technology.com/news/boehringers-nintedanib-breakthrough-status/
https://www.prnewswire.com/news-releases/fda-grants-ofev-breakthrough-therapy-designation-for-chronic-fibrosing-ilds-with-a-progressive-phenotype-300936171.html
https://endpts.com/boehringer-ingelheims-ofev-wins-fda-approval-for-use-in-scleroderma-patients/
https://in.reuters.com/article/us-boehringer-fda/fda-approves-boehringers-lung-disease-drug-idINKCN1VR2KH
https://www.thepharmaletter.com/article/ofev-set-for-new-us-approval-in-scleroderma
http://www.pharmatimes.com/news/boehringer_expands_ipf_pipeline_with_addition_of_bbt-877_1294890
http://www.pharmatimes.com/news/nintedanib_hits_targets_in_rare_lung_disease_trial_1288949
http://www.pmlive.com/pharma_news/boehringer_eyes_rare_disease_use_for_respiratory_blockbuster_1288847
https://www.businesswire.com/news/home/20190520005645/en/Phase-III-study-showed-nintedanib-slows-loss/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.biospace.com/article/genentech-plans-legal-battle-to-protect-esbriet-from-generic-competition/
http://www.businesskorea.co.kr/news/articleView.html?idxno=28204
https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM293268.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-nintedanib-100-mg-and-150-mg-capsules-ofev-205832-1545895347.pdf
https://www.prnewswire.com/news-releases/new-study-results-provide-evidence-that-ofev-nintedanib-slows-progression-of-ipf-beyond-four-years-with-consistent-safety-300713093.html
http://www.pharmatimes.com/news/boehringer_sales_rise_as_jardiance_and_ofev_thrive_1246469
https://www.prnewswire.com/news-releases/efficacy-and-safety-of-ofev-nintedanib-reinforced-in-new-presentations-at-ats-2018-300650584.html
https://www.biospace.com/article/releases/fda-grants-fast-track-designation-to-nintedanib-for-the-treatment-of-systemic-sclerosis-with-associated-interstitial-lung-disease/
http://www.pharmatimes.com/news/pim_status_for_boehringers_mesothelioma_drug_1215220
https://globenewswire.com/news-release/2017/08/07/1081287/0/en/FibroGen-Announces-Positive-Topline-Results-from-Phase-2-Study-of-Pamrevlumab-in-Idiopathic-Pulmonary-Fibrosis.html
http://www.prnewswire.com/news-releases/ipf-patients-treated-with-ofev-nintedanib-versus-placebo-were-twice-as-likely-to-have-improved-or-stable-lung-function-300462288.html
http://www.reuters.com/article/us-merck-co-britain-remicade-idUSKBN18J12Z
http://www.prnewswire.com/news-releases/nintedanib-granted-orphan-drug-designation-for-treatment-of-mesothelioma-300378258.html
http://www.fiercebiotech.com/biotech/bristol-myers-pens-100m-nash-fibrosis-drug-deal-japan-s-nitto
http://www.pharmatimes.com/news/bi_unveils_new_data_backing_ipf_drug_ofev_1174585
http://www.fiercepharma.com/marketing/bi-s-vargatef-comes-up-one-endpoint-short-colorectal-cancer-effort
Market Place
Share 
